Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2021
Price :
$35
*
At a glance
- Drugs Lemborexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 01 Jan 2021 Results assessing potential of lemborexant for residual morning and next-day effects, including somnolence from 9 studies (E2006-A001-001 Part B, E2006-A001-002, E2006-A001-003, E2006-E044-106, E2006-A001-107, E2006-A001-108, E2006-G000-201, E2006-G000-303 & E2006-G000-304) published in the Postgraduate Medicine.
- 07 Dec 2017 According to an Eisai media release, results from this trial have been published in the Journal of Clinical Sleep Medicine.
- 20 May 2017 Results presented at the 2017 Annual Scientific Meeting of the American Geriatrics Society